The last and first frontier - Emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants

Journal of the International AIDS Society

Volumn 18, Issue , 2015, Pages

  Cotton, Mark F ^a   Holgate, Sandi ^a   Nelson, Aurelie ^b   Rabie, Helena ^a   Wedderburn, Catherine ^b   Mirochnick, Mark ^c  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretrovirals; Low birth weight; Management; Premature; Small for gestation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; STAVUDINE; ZIDOVUDINE;

EARLY DIAGNOSIS; FEEDING DIFFICULTY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; NEWBORN; NEWBORN APNEA; NEWBORN INFECTION; NEWBORN SEPSIS; POST EXPOSURE PROPHYLAXIS; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; REVIEW; SMALL FOR DATE INFANT; VERTICAL TRANSMISSION; VIRUS REPLICATION; FEMALE; HIV INFECTIONS; INFANT; PREVENTION AND CONTROL;

FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEVIRAPINE; PREGNANCY; ZIDOVUDINE;

EID: 84960154512     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.7.20271     Document Type: Review

References (49)

1. UNAIDS (2008). The first 10 years. Geneva, Switzerland: UNAIDS.
2. UNAIDS (2014). 90-90-90 - an ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland: UNAIDS.
3. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233-44.
4. Innes S, Lazarus E, Otwombe K, Liberty A, Germanus R, Van Rensburg AJ, et al. Early severe HIV disease precedes early antiretroviral therapy in infants: are we too late? J Int AIDS Soc. 2014;17(1):18914, doi: http://dx.doi.org/10.7448/IAS.17.1.18914
5. Lilian RR, Kalk E, Technau KG, Sherman GG. Birth diagnosis of HIV infection in infants to reduce infant mortality and monitor for elimination of mother-to-child transmission. Pediatr Infect Dis J. 2013;32(10):1080-5.
6. Dinh TH, Delaney KP, Goga A, Jackson D, Lombard C, Woldesenbet S, et al. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4-8 weeks postpartum in South Africa 2011-2012: a national population-based evaluation. PLoS One. 2015;10(5):e0125525.
7. Kuhn L, Abrams EJ, Matheson PB, Thomas PA, Lambert G, Bamji M, et al. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS. 1997;11(4):429-35.
8. Kuhn L, Steketee RW, Weedon J, Abrams EJ, Lambert G, Bamji M, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. Perinatal AIDS Collaborative Transmission Study. J Infect Dis. 1999; 179(1):52-8.
9. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2008;22(2):289-99.
10. Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. New Engl J Med. 2012;366(25):2368-79.
11. Guidelines for the use of antiretroviral agents in pediatric HIV infection. [cited 2014 Feb 21]. Available from: http://aidsinfo.nih.gov/guidelines
12. Chiappini E, Galli L, Giaquinto C, Ene L, Goetghebuer T, Judd A, et al. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS. 2013; 27(6):991-1000.
13. Bitnun A, Samson L, Chun TW, Kakkar F, Brophy J, Murray D, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborn infants can achieve sustained virologic suppression with low frequency of CD4+ T-cells carrying HIV in peripheral blood. Clin Infect Dis. 2014;59(7):1012-9.
14. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun TW, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369(19):1828-35.
15. Luzuriaga K, Gay H, Ziemniak C, Sanborn KB, Somasundaran M, Rainwater-Lovett K, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med. 2015;372(8):786-8.
16. Care of the preterm and/or low-birth-weight newborn. [cited 2015 Apr 26]. Available from: http://www.who.int/maternal-child-adolescent/topics/newborn/care-of-preterm/en/
17. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A-B, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162-72.
18. Marchant T, Willey B, Katz J, Clarke S, Kariuki S, ter Kuile F, et al. Neonatal mortality risk associated with preterm birth in East Africa, adjusted by weight for gestational age: individual participant level meta-analysis. PLoS Med. 2012;9(8):e1001292.
19. Lloyd LG, de Witt TW. Neonatal mortality in South Africa: how are we doing and can we do better? S Afr Med J. 2013;103(8):518-9.
20. Tooke L, Horn AR, Harrison MC. HIV transmission to extremely low birth weight infants. Pediatr Infect Dis J. 2013;32(1):36-8.
21. Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, et al. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health. 2013;10(Suppl 1):S2.
22. Lee AC, Katz J, Blencowe H, Cousens S, Kozuki N, Vogel JP, et al. National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. Lancet Glob Health. 2013;1(1):e26-36.
23. Approach to the child with IUGR/SGA. [cited 2015 Aug 10]. Available from: learnpediatrics.com/body-systems/neonate/approach-to-the-child-with-iugrsga
24. Pillay T, Khan M, Moodley J, Adhikari M, Coovadia H. Perinatal tuberculosis and HIV-1: considerations for resource-limited settings. Lancet Infect Dis. 2004; 4(3):155-65.
25. Bekker A, Du Preez K, Schaaf HS, Cotton MF, Hesseling AC. High tuberculosis exposure among neonates in a high tuberculosis and human immunodeficiency virus burden setting. Int J Tuberc Lung Dis. 2012;16(8):1040-6.
26. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(11):1695-705.
27. Behrman RE, Butler AS, editors. Preterm birth: causes, consequences, and prevention. Washington, DC: National Academies Press; 2007.
28. Desfrere L, de Oliveira I, Goffinet F, El Ayoubi M, Firtion G, Bavoux F, et al. Increased incidence of necrotizing enterocolitis in premature infants born to HIV-positive mothers. AIDS. 2005;19(14):1487-93.
29. Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2012;129(3):e827-41.
30. Tenovuo A. Neonatal complications in small-for-gestational age neonates. J Perinat Med. 1988;16:197-202.
31. Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006;45(7):683-704.
32. Ku LC, Smith PB. Dosing in neonates: special considerations in physiology and trial design. Pediatr Res. 2015;77(1-1):2-9.
33. Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Veloso VG, Rossi S, et al. Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life. Pediatr Infect Dis J. 2011;30(9):769-72.
34. Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KH, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol. 2001;41(7): 732-41.
35. Mirochnick M, Capparelli E, Dankner W, Sperling RS, van Dyke R, Spector SA. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother. 1998;42(4):808-12.
36. de Waal R, Kroon SM, Holgate SL, Horn AR, Tooke LJ, Norman J, et al. Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations. Pediatr Infect Dis J. 2014; 33(12):1231-3.
37. Mugabo P, Els I, Smith J, Rabie H, Smith P, Mirochnick M, et al. Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. S Afr Med J. 2011; 101(9):655-8.
38. Oudijk JM, McIlleron H, Mulenga V, Chintu C, Merry C, Walker AS, et al. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. AIDS. 2012;26(12):1523-8.
39. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem. 1994;269(27):17960-4.
40. Clarke DF, Wong RJ, Wenning L, Stevenson DK, Mirochnick M. Raltegravir in vitro effect on bilirubin binding. Pediatr Infect Dis J. 2013;32(9):978-80.
41. Silverman WA, Andersen DH, Blanc WA, Crozier DN. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics. 1956;18(4):614-25.
42. Ahlfors CE. Unbound bilirubin associated with kernicterus: a historical approach. J Pediatr. 2000;137(4):540-4.
43. Boxwell D, Cao K, Lewis L, Marcus K, Nikhar B. Neonatal toxicity of Kaletra oral solution - LPV, ethanol, or propylene glycol? 18th Congress of Retrovirology and Opportunistic Infection; February 27-March 2, Boston, MA; 2011.
44. Holgate S, Rabie H, Smith P, Cotton MF. Trough lopinavir concentrations in preterm human immunodeficiency virus-infected infants. Pediatr Infect Dis J. 2012;31(6):602-4.
45. Urien S, Firtion G, Anderson ST, Hirt D, Solas C, Peytavin G, et al. Lopinavir/ritonavir population pharmacokinetics in neonates and infants. Br J Clin Pharmacol. 2011;71(6):956-60.
46. Klein R. Approved and tentatively approved antiretrovirals in association with the president's emergency plan. Silver Spring, MD: Food and Drug Administration; 2015.
47. Israel-Ballard K, Chantry C, Dewey K, Lonnerdal B, Sheppard H, Donovan R, et al. Viral, nutritional, and bacterial safety of flash-heated and pretoria-pasteurized breast milk to prevent mother-to-child transmission of HIV in resource-poor countries: a pilot study. J Acquir Immune Defic Syndr. 2005; 40(2):175-81.
48. Nelson A, Maritz J, Giddy J, Frigati L, Rabie H, Van Cutsem G, et al. HIV testing and antiretroviral therapy initiation at birth: views from a primary care setting in Khayelitsha. S Afr J HIV Med. 2015;16:4.
49. Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2013;16:18588, doi: http://dx.doi.org/10.7448/IAS.16.1.18588